Pamlectabart Tismanitin (HDP-101) is an investigational BCMA-targeted antibody drug conjugate (ADC).
| SparkCures ID | 416 |
|---|---|
| Developed By | Heidelberg Pharma |
| Generic Name | Pamlectabart Tismanitin (HDP-101) |
| Treatment Classifications | |
| Treatment Targets |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
February 10, 2021